Recent News

• 10.27.2026 - Enlivex Announces Receipt of Delisting Notice from Nasdaq; Intends to Appeal
• 10.22.2026 - Enlivex Announces 1-for-16 Reverse Share Split to be Effective October 27, 2026
• 10.19.2026 - Enlivex Announces Cost Reduction Plan to Focus Resources on Phase 2b Trial of Allocetra™ in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis
• 09.22.2026 - Enlivex Announces Termination of Previously-Announced Financing Payable in RAIN Tokens
• 07.30.2026 - Enlivex Treasury Portfolio Update: RAIN Trading Volume Reaches $860MM, 622% Month-Over-Month Growth in July vs June
• 07.29.2026 - Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones
• 07.28.2026 - Enlivex Announces $400,000,000 Private Placement
• 07.20.2026 - Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion
• 07.13.2026 - Enlivex Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Allocetra™ in Age-Related Knee Osteoarthritis
• 07.07.2026 - Enlivex Announces 1-for-15 Reverse Stock Split Effective July 9, 2026

Recent Filings

• 10.27.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 10.27.2026 - EX-99.1 EX-99.1
• 10.22.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 10.22.2026 - EX-99.1 EX-99.1
• 10.19.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 10.19.2026 - EX-99.1 EX-99.1
• 10.02.2026 - 6-K/A Report of foreign issuer [Rules 13a-16 and 15d-16]
• 10.01.2026 - 6-K/A Report of foreign issuer [Rules 13a-16 and 15d-16]
• 09.29.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 09.29.2026 - EX-99.1 EX-99.1